CN114149432B - 用于癌症治疗的双重clk/cdk1抑制剂 - Google Patents

用于癌症治疗的双重clk/cdk1抑制剂 Download PDF

Info

Publication number
CN114149432B
CN114149432B CN202111328981.9A CN202111328981A CN114149432B CN 114149432 B CN114149432 B CN 114149432B CN 202111328981 A CN202111328981 A CN 202111328981A CN 114149432 B CN114149432 B CN 114149432B
Authority
CN
China
Prior art keywords
another aspect
group
alkyl
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111328981.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114149432A (zh
Inventor
托马斯·R·韦伯
朴在显
钱德达莉亚·拉吉塞蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Priority to CN202111328981.9A priority Critical patent/CN114149432B/zh
Publication of CN114149432A publication Critical patent/CN114149432A/zh
Application granted granted Critical
Publication of CN114149432B publication Critical patent/CN114149432B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202111328981.9A 2016-09-30 2017-09-29 用于癌症治疗的双重clk/cdk1抑制剂 Active CN114149432B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111328981.9A CN114149432B (zh) 2016-09-30 2017-09-29 用于癌症治疗的双重clk/cdk1抑制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662402876P 2016-09-30 2016-09-30
US62/402,876 2016-09-30
CN201780067717.XA CN109937039A (zh) 2016-09-30 2017-09-29 用于癌症治疗的双重clk/cdk1抑制剂
PCT/US2017/054442 WO2018064545A1 (en) 2016-09-30 2017-09-29 Dual clk/cdk1 inhibitors for cancer treatment
CN202111328981.9A CN114149432B (zh) 2016-09-30 2017-09-29 用于癌症治疗的双重clk/cdk1抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780067717.XA Division CN109937039A (zh) 2016-09-30 2017-09-29 用于癌症治疗的双重clk/cdk1抑制剂

Publications (2)

Publication Number Publication Date
CN114149432A CN114149432A (zh) 2022-03-08
CN114149432B true CN114149432B (zh) 2024-07-05

Family

ID=61760971

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111328981.9A Active CN114149432B (zh) 2016-09-30 2017-09-29 用于癌症治疗的双重clk/cdk1抑制剂
CN201780067717.XA Pending CN109937039A (zh) 2016-09-30 2017-09-29 用于癌症治疗的双重clk/cdk1抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780067717.XA Pending CN109937039A (zh) 2016-09-30 2017-09-29 用于癌症治疗的双重clk/cdk1抑制剂

Country Status (5)

Country Link
US (2) US10722515B2 (https=)
EP (2) EP4086257A1 (https=)
JP (1) JP2019533652A (https=)
CN (2) CN114149432B (https=)
WO (1) WO2018064545A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
CN114149432B (zh) 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
WO2020006115A1 (en) * 2018-06-26 2020-01-02 Betty Tam Methods of treating cancer using a clk inhibitor
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
CN113384703B (zh) * 2021-06-21 2023-03-10 深圳市第二人民医院(深圳市转化医学研究院) Dhx34基因的表达抑制剂在制备抑制肝癌细胞转移和侵袭的药物中的应用
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途
WO2025243082A2 (en) * 2024-05-24 2025-11-27 The Chinese University Of Hong Kong Covalent protein-protein interaction inhibitor against srpks

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
BR9611157A (pt) * 1995-11-01 1999-03-30 Novartis Ag Derivados de purina e processos para sua preparação
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
CA2394654A1 (en) * 1999-12-17 2001-06-21 Manfred Weigele Proton pump inhibitors
US20020103161A1 (en) * 1999-12-17 2002-08-01 Manfred Weigele Novel heterocycles
ATE345349T1 (de) * 1999-12-17 2006-12-15 Ariad Pharma Inc Purinderivate
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2009085226A2 (en) * 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibitors of cdc2-like kinases (clks) and methods of use thereof
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
WO2013144532A1 (en) 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
WO2013171473A1 (en) 2012-05-15 2013-11-21 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2017210138A1 (en) 2016-05-31 2017-12-07 The J. David Gladstone Institutes In vitro methods of differentiating stem cells into neurons and neurons generated using the same
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore;Yihui Shi et al.;《Bioorganic & Medicinal Chemistry Letters》;第27卷;第406-412页 *

Also Published As

Publication number Publication date
WO2018064545A1 (en) 2018-04-05
CN109937039A (zh) 2019-06-25
EP3518925A1 (en) 2019-08-07
US20190255059A1 (en) 2019-08-22
US10722515B2 (en) 2020-07-28
US20200390772A1 (en) 2020-12-17
JP2019533652A (ja) 2019-11-21
US11337981B2 (en) 2022-05-24
EP4086257A1 (en) 2022-11-09
EP3518925A4 (en) 2020-04-15
CN114149432A (zh) 2022-03-08

Similar Documents

Publication Publication Date Title
CN114149432B (zh) 用于癌症治疗的双重clk/cdk1抑制剂
US20250188080A1 (en) Imidazolonylquinoline compounds and therapeutic uses thereof
CN114728938B (zh) 作为prmt5抑制剂的四氢异喹啉螺环化合物
CN103889962B (zh) 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
RU2691105C1 (ru) Лекарственные соединения
CN115504980B (zh) 嘧啶并含氮六元芳香杂环类化合物及其用途
US20170190693A1 (en) Substituted chromanes and method of use
EP3943086A1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
US20100184790A1 (en) Pyrrolo[2,3-b]pyridine compounds, azaindole compounds used for synthesizing said pyrrolo[2,3-b]pyridine compounds, methods for the production thereof, and uses thereof
JP2013529212A (ja) ｍＴＯＲ選択的キナーゼ阻害剤
EP3166945B1 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
TW202510857A (zh) 化合物及其用途
US11254654B2 (en) Heterochromatin gene repression inhibitors
CA3102458A1 (en) Oga inhibitor compounds
AU2019289969A1 (en) OGA inhibitor compounds
CN117377676B (zh) 嘌呤衍生物的晶型及其药物组合物
KR102352624B1 (ko) LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
US20250177539A1 (en) Er degraders and uses thereof
EP4731223A1 (en) Morpholine and 1,4-oxazepane compounds and its use in therapy
HK40068646A (en) Imidazolonylquinoline compounds and therapeutic uses thereof
HK40068646B (en) Imidazolonylquinoline compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant